

BIOCON GROUP

FINANCIALS

H1 FY 2005 vs H1 FY 2004

Q2 FY 2005 vs Q2 FY 2004

FACT SHEET

BIOCON LIMITED (CONSOLIDATED)							
PROFIT & LOSS STATEMENT							(Rs. crores)
Particulars	Q2 FY 2005	Q2 FY 2004	Variance Q2 FY 05 vs Q2 FY 04	H1 FY 2005	H1 FY 2004	Variance H1 FY 05 vs H1 FY 04	Full Year ended March 31, 2004
INCOME							
Biopharmaceuticals	147	124	19%	287	208	38%	436
Enzymes	24	16	50%	44	32	38%	66
Contract research fees	15	10	58%	29	17	71%	39
Other income	3	1	200%	7	1	600%	1
Total	189	151	26%	367	258	42%	542
EXPENDITURE							
Manufacturing & other exp	124	99	26%	245	171	43%	362
PBIDT	65	52	24%	122	87	40%	180
Interest and finance charges	0	1	-100%	1	1	3%	2
PBDT	65	51	27%	121	86	41%	178
Depreciation	5	4	21%	9	8	21%	16
PBT	60	47	29%	112	78	44%	162
Taxes	4	10	-61%	7	18	-59%	23
PROFIT FOR THE PERIOD	56	37	52%	105	60	74%	139
Minority interest	(0)	0		(0)	0	0%	0
NET PROFIT (PAT)	56	37	52%	105	60	75%	139
EPS – (Rs)	5.63	4.13	36%	10.50	6.68	57%	13.87
NOTE: The figures are rounded off to nearest crores, percentages are on absolute numbers							

BIOCON LIMITED (CONSOLIDATED)			
BALANCE SHEET			(Rs. crores)
Particulars	As on 30-Sep-04	As on 30-Sep-03	As on 31-Mar-04
<u>SOURCES OF FUNDS</u>			
Share Capital	50	2	50
Reserves & Surplus	620	193	513
Total Shareholder's Funds	670	195	563
Minority interest	1	0	0
Deferred Tax Liability	19	15	18
Secured Loans	74	48	47
Unsecured Loans	22	14	17
Total Loan Funds	96	62	64
Total	786	272	645
<u>APPLICATION OF FUNDS</u>			
Fixed Assets	365	176	219
Investments	337	10	22
Inventories	76	44	86
Sundry debtors	148	129	119
Cash and bank balances	2	3	317
Loans and advances	21	18	23
Total Current Assets, Loans & Advances	246	193	544
Less: Current liabilities and provisions	162	107	140
Net Current assets	84	86	404
Total	786	272	645

BIOCON LIMITED (CONSOLIDATED)			
STATEMENT OF CASH FLOWS			<i>(Rs. crores)</i>
Particulars	H1 FY 2005	H1 FY 2004	Full Year ended March 31, 2004
<u>I. Cash Flow from Operating Activities</u>			
Net profit before tax	112	78	162
Less/Add: non-cash items/ items required separately			
Depreciation	9	8	16
Others	(3)	3	2
Changes in working capital and other provisions	(32)	(31)	(32)
Cash generated from operations	86	58	148
Tax paid (net of refunds)	(3)	(7)	(20)
Net Cash provided by operating activities	83	51	128
<u>II. Cash Flow from Investing Activities</u>			
Fixed Assets	(120)	(38)	(93)
Interest / dividend received	7	0	2
Investments	(314)	(5)	(17)
Net cash used for investing activities	(427)	(43)	(108)
<u>III. Cash Flows from Financing Activities</u>			
Proceeds from issuance of share capital (net of expenses)	0	0	300
Borrowings and other financing activities	29	(8)	(6)
Net Cash provided/(used) for financing activities	29	(8)	294
<u>IV. Net Change in Cash and Cash Equivalents (I+II+III)</u>	(315)	(0)	314
<u>V. Cash & Cash Eq. at the beginning of the year</u>	317	3	3
<u>VI CASH AND CASH EQUIVALENTS OF THE ESOP TRUST ACQUIRED DURING THE YEAR</u>	0	0	0
<u>VI. Cash and Cash Eq. at the end of the year (IV+V)</u>	2	3	317

BIOCON LIMITED (STANDALONE)							
PROFIT & LOSS STATEMENT							(Rs. crores)
Particulars	Q2 FY 2005	Q2 FY 2004	Variance Q2 FY 05 vs Q2 FY 04	H1 FY 2005	H1 FY 2004	Variance H1 FY 05 vs H1 FY 04	Full Year ended March 31, 2004
INCOME							
Sales	171	140	21%	331	240	38%	502
Contract research fees	0	0		0	0		1
Other income	3	1	497%	7	1	1134%	1
Total	174	141	23%	338	241	40%	503
EXPENDITURE							
Manufacturing & other exp	116	93	25%	229	161	42%	341
PBIDT	58	48	20%	109	80	36%	163
Interest and finance charges	1	0	249%	1	1	3%	2
PBDT	57	48	19%	108	79	36%	161
Depreciation	4	4	10%	8	7	19%	14
PBT	53	44	20%	100	73	38%	148
Taxes	3	10	-66%	7	18	-61%	23
NET PROFIT (PAT)	50	34	47%	93	55	69%	125
EPS – (Rs)	5.02	3.82	31%	9.34	6.12	53%	12.47
NOTE: The figures are rounded off to nearest crores, percentages are on absolute numbers							

SYNGENE INTERNATIONAL PRIVATE LIMITED (STANDALONE)							
PROFIT & LOSS STATEMENT							(Rs. crores)
Particulars	Q2 FY 2005	Q2 FY 2004	Variance Q2 FY 05 vs Q2 FY 04	H1 FY 2005	H1 FY 2004	Variance H1 FY 05 vs H1 FY 04	Full Year ended March 31, 2004
INCOME							
Contract research fees	13	7	96%	25	14	81%	32
Sale of compounds	2	3	-34%	4	3	46%	6
Other income	0	0		0	0		0
Total	15	10	55%	29	17	73%	38
EXPENDITURE							
Contract research & other exp	7	5	44%	14	9	58%	20
PBDIT	8	5	66%	15	8	90%	18
Interest and finance charges	0	0		0	0		0
PBDT	8	5	66%	15	8	91%	18
Depreciation	1	1	1%	1	1	10%	2
PBT	7	4	70%	14	7	103%	16
Taxes	0	0	5%	0	0	98%	0
NET PROFIT (PAT)	7	4	73%	14	7	105%	16

NOTE: The figures are rounded off to nearest crores, percentages are on absolute numbers

CLINIGENE INTERNATIONAL PRIVATE LIMITED (STANDALONE)							
PROFIT & LOSS STATEMENT							(Rs. crores)
Particulars	Q2 FY 2005	Q2 FY 2004	Variance Q2 FY 05 vs Q2 FY 04	H1 FY 2005	H1 FY 2004	Variance H1 FY 05 vs H1 FY 04	Full Year ended March 31, 2004
INCOME							
Contract research fees	0	0		0	0		1
Other income	0	0		0	0		0
Total	0	0		0	0		1
EXPENDITURE							
Contract research & other exp	1	1	4%	2	1	41%	3
PBDIT	(1)	(1)	2%	(2)	(1)	35%	(2)
Interest and finance charges	0	0		0	0		0
PBDT	(1)	(1)	2%	(2)	(1)	35%	(2)
Depreciation	0	0		0	0		0
PBT	(1)	(1)	20%	(2)	(1)	51%	(2)
Taxes	0			0	0	0	0
NET PROFIT /(LOSS)	(1)	(1)	20%	(2)	(1)	51%	(2)
NOTE: The figures are rounded off to nearest crores, percentages are on absolute numbers							